Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Pharmaceuticals Holding Co Ltd    601607   CNE000000C82

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Shanghai Pharmaceuticals : Advent, Shanghai Pharma have not approached Stada - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2017 | 08:54pm CEST
Logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel

German drug company Stada Arzneimittel AG has not been approached by Advent International or Shanghai Pharmaceuticals Holding with a counter offer, two sources close to the matter told Reuters on Monday.

Rival buyout firms Bain and Cinven had offered to buy Stada in April, which seemed to end the contest to acquire the generic drug maker, but Bloomberg reported on Monday that Advent and Shanghai Pharmaceuticals are considering making an offer.

Bain and Cinven's offer of 65.28 euros per share and a dividend of 0.72 euros per Stada share was a surprisingly large increase on a previous bid and valued the company at about 5.3 billion euros (4.5 billion pounds).

Bloomberg reported that Advent and Shanghai Pharmaceuticals are discussing a potential bid of about 70 euros a share, citing people familiar with the matter.

However, Reuters' sources said a fresh bid from the duo is unlikely.

"Shanghai Pharmaceuticals is expected to struggle to secure the financing for a possible counterbid," the sources said. "They don’t have much time left to challenge Bain and Cinven."

Advent and Stada declined to comment and Reuters was unable to contact Shanghai Pharmaceuticals outside business hours.

(Additional reporting by Subrat Patnaik in Bengaluru; Editing by David Goodman)

By Alexander Hübner and Pamela Barbaglia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGHAI PHARMACEUTICALS H
10/20 SHANGHAI PHARMACEUTICALS : SH Pharma confirms bids for Cardinal's PRC business
10/18 SHANGHAI PHARMACEUTICALS : ·clarification announcement
10/18 SHANGHAI PHARMACEUTICALS : ·Notice of Board Meeting
09/26 SHANGHAI PHARMACEUTICALS : CVC, others explore sale of drugmaker Alvogen - Bloom..
08/30 SHANGHAI PHARMACEUTICALS : SH Pharma interim net up 11% to Rmb1.93bn; no div
08/28 SHANGHAI PHARMACEUTICALS : Realized Stable and Healthy Growth in Interim Results
08/23SHANGHAI PHARMACEUTICALS HOLDING CO : half-yearly earnings release
08/15 Pharmas vie over $3b US acquisition
08/15 Pharma companies eye US acquisition
08/14 SHANGHAI PHARMACEUTICALS : ·clarification announcement
More news
News from SeekingAlpha
07/30 WEEK IN REVIEW : Vivace Details Its Capital Efficient Plan To Develop Novel Canc..
2015 WEEK IN REVIEW : Hepalink Pharma Buys U.S.-Based CMO Cytovance
2015 WEEK IN REVIEW : Porton Fine Chemicals Buys Dongbang Pharma
Financials ( CNY)
Sales 2017 137 B
EBIT 2017 4 905 M
Net income 2017 3 605 M
Debt 2017 3 065 M
Yield 2017 1,45%
P/E ratio 2017 18,84
P/E ratio 2018 16,59
EV / Sales 2017 0,47x
EV / Sales 2018 0,43x
Capitalization 61 794 M
Chart SHANGHAI PHARMACEUTICALS H
Duration : Period :
Shanghai Pharmaceuticals H Technical Analysis Chart | 601607 | CNE000000C82 | 4-Traders
Technical analysis trends SHANGHAI PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 25,1  CNY
Spread / Average Target -1,2%
EPS Revisions
Managers
NameTitle
Min Zuo President & Executive Director
Jun Zhou Chairman
You Li Xu Chairman-Supervisory Board
Bo Shen Chief Financial Officer, Director & Vice President
Xin Chen Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
SHANGHAI PHARMACEUTICALS HOLDING CO LTD25.26%9 297
SINOPHARM HOLDING CO LTD8.92%12 375
TSURUHA HOLDINGS INC.26.76%6 054
SUNDRUG CO LTD21.38%5 798
COSMOS PHARMACEUTICAL CORP10.81%4 272
SUGI HOLDINGS CO.,LTD.5.76%3 294